DelMar Pharmaceuticals (NASDAQ:DMPI) announced its quarterly earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.03, Fidelity Earnings reports.
DelMar Pharmaceuticals stock opened at $0.55 on Friday. DelMar Pharmaceuticals has a one year low of $0.40 and a one year high of $6.29. The company has a 50-day simple moving average of $0.59 and a 200-day simple moving average of $0.71. The firm has a market capitalization of $6.27 million, a P/E ratio of -0.29 and a beta of 1.30.
DMPI has been the subject of a number of analyst reports. Zacks Investment Research upgraded DelMar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 29th. Maxim Group reaffirmed a “buy” rating on shares of DelMar Pharmaceuticals in a research report on Friday, November 15th.
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.
Featured Story: What is included in the gross domestic product?
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.